Skip to content
For US Healthcare Professionals Patient Site
Picture of LEMTRADA patient Ginny. Picture of LEMTRADA patient Ginny.
Ginny
38
Phoenix, AZ
married, mother of 3, motorcycle enthusiast
“I had tried multiple treatments unsuccessfully in a short period of time. I felt like a pawn in the process.”

DISEASE HISTORY

6 Years

since RMS diagnosis

PATIENT BACKGROUND

RMS Risk Factors

incomplete recovery from relapse

RMS TREATMENT HISTORY

5 prior DMTs:
2 injectables,
2 oral treatments,
and 1 infusion therapy

WHAT MOTIVATED YOU TO EXPLORE OTHER TREATMENT OPTIONS?

Despite taking multiple therapies, I was still experiencing relapses and disability progression. I wanted to find out more about the efficacy and safety of LEMTRADA and was intrigued by the dosing schedule because it was different from what I was used to.

HOW DID YOU HANDLE ANY CONCERNS ABOUT SAFETY?

I wasn’t sure that I fully understood the full safety profile so I sought the advice of specialists who educated me about things like the potential autoimmune side effects and required monthly monitoring. After learning more, I felt comfortable moving forward with LEMTRADA.

DID YOU FEEL PREPARED FOR YOUR INFUSIONS?

Before my first course, my doctor explained the infusion process. By the second course of LEMTRADA, I knew to take into account how I would feel when scheduling my infusion days. It took some planning on my part, but by the second infusion I felt well prepared.

WHAT WOULD YOU TELL SOMEONE CONSIDERING LEMTRADA?

Spend the time you need to get the information you want to help you make the most informed decision. Understand what LEMTRADA entails and make sure you can fully commit to all that is required.

Are your patients interested in learning
more about LEMTRADA?

Download the full patient resource

INDICATION

LEMTRADA is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include relapsing-remitting disease and active secondary progressive disease, in adults. Because of its safety profile, the use of LEMTRADA should generally be reserved for patients who have had an inadequate response to two or more drugs indicated for the treatment of MS.

Limitations of Use: LEMTRADA is not recommended for use in patients with clinically isolated syndrome (CIS) because of its safety profile.

IMPORTANT SAFETY INFORMATION

WARNING: AUTOIMMUNITY, INFUSION REACTIONS, STROKE AND MALIGNANCIES

CONTRAINDICATIONS

LEMTRADA is contraindicated in patients:

WARNINGS AND PRECAUTIONS

Most Common Adverse Reactions

In controlled clinical trials, the most common adverse reactions (incidence ≥10% and >interferon beta-1a) with LEMTRADA vs interferon beta-1a were: rash (53% vs 6%), headache (52% vs 23%), pyrexia (29% vs 9%), nasopharyngitis (25% vs 19%), nausea (21% vs 9%), urinary tract infection (19% vs 8%), fatigue (18% vs 13%), insomnia (16% vs 15%), upper respiratory tract infection (16% vs 13%), herpes viral infection (16% vs 3%), urticaria (16% vs 2%), pruritus (14% vs 2%), thyroid gland disorders (13% vs 3%), fungal infection (13% vs 4%), arthralgia (12% vs 9%), pain in extremity (12% vs 9%), back pain (12% vs 8%), diarrhea (12% vs 6%), sinusitis (11% vs 8%), oropharyngeal pain (11% vs 5%), paresthesia (10% vs 8%), dizziness (10% vs 5%), abdominal pain (10% vs 5%), flushing (10% vs 4%), and vomiting (10% vs 3%).

Use in Specific Populations

Physicians are encouraged to report pregnancies by calling 1-800-745-4447, option 2. Antibodies, including anti-CD52 and autoantibodies, may be transferred from the mother to the fetus during pregnancy. Placental transfer of anti-thyroid antibodies resulting in neonatal Graves’ disease has been reported.

Safety and effectiveness in pediatric patients less than 17 years of age have not been established. Use of LEMTRADA is not recommended in pediatric patients due to the risks of autoimmunity and infusion reactions, stroke, and because it may increase the risk of malignancies.

Please see full Prescribing Information, including Boxed WARNING.

Indication

LEMTRADA is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include relapsing-remitting disease and active secondary progressive disease, in adults. Because of its safety profile, the use of LEMTRADA should generally be reserved for patients who have had an inadequate response to two or more drugs indicated for the treatment of MS.

Limitations of Use: LEMTRADA is not recommended for use in patients with clinically isolated syndrome (CIS) because of its safety profile.

IMPORTANT SAFETY INFORMATION

WARNING: AUTOIMMUNITY, INFUSION REACTIONS, STROKE AND MALIGNANCIES

  • LEMTRADA causes serious, sometimes fatal, autoimmune conditions such as immune thrombocytopenia and anti-glomerular basement membrane (anti-GBM) disease. Monitor complete blood counts with differential, serum
Alternate Text